Personalis is a publicly listed company tracked for investment-relevant business developments.
Personalis' next-generation sequencing technology, originally developed for blood-based trace cancer detection, is the critical enabler for calibrating personalized mRNA cancer vaccines by comparing tumor and bloodstream expression profiles.